FBXO2 modulates STAT3 signaling to regulate proliferation and tumorigenicity of osteosarcoma cells.

BACKGROUND: Osteosarcoma (OS) is the most common primary bone malignancy in children and adolescents, and hyperproliferation of cells is a major problem of OS. FBXO2 belongs to the family of F-box proteins, and is a substrate recognition component of the Skp1-Cul1-F-box protein (SCF) E3 ubiquitin ligase complex with specificity for high-mannose glycoproteins. The aim of the present study was to investigate the critical role of FBXO2 in OS cells. METHODS: The protein and mRNA expression levels of FBXO2 in clinic OS patients were measured by quantitative real time-polymerase chain reaction (qRT-PCR), Western blot and Immunohistochemical (IHC) staining assays, respectively. The FBXO2 overexpression model was constructed by retro-virus transfection in OS cells. FBXO2 knockout (KO) cells were generated by Clustered regularly interspaced short palindromic repeat (CRISPR)-CRISPR-associated protein 9 (Cas9) assay. Cell counting and colony formation assays were used to analyze the effect of FBXO2 on the biological function of OS cells. FBXO2 KO cells were injected into nude mice to observe tumor growth in vivo. The interaction between FBXO2 and IL-6 was detected by immunoprecipitation. Luciferase assay was used to determine the transcriptional activity of STAT3. RESULTS: Here, we show that FBXO2 is significantly up-regulated in clinical OS samples compared to adjacent normal tissues. Ectopic expression of FBXO2 leads to increased OS cell proliferation and colony-forming ability, while FBXO2 knockout by CRISPR-Cas9-based gene editing has the opposite effect. In addition, the glycoprotein recognition activity of FBXO2 is required for its biological function in OS. In vivo experiments showed that FBXO2 knockout greatly impaired the tumorigenicity of OS cells in nude mice. At the molecular level, we found that knocking out FBXO2 can significantly inhibit STAT3 phosphorylation and downstream target gene expression through IL-6R stabilization. CONCLUSION: Together, these results indicate that FBXO2 promotes OS development by activating the STAT3 signaling pathway, suggesting that FBXO2 may be a new target for OS treatment.

MicroRNA­671­3p regulates the development of knee osteoarthritis by targeting TRAF3 in chondrocytes.

Osteoarthritis (OA) is a degenerative joint disease characterized by articular cartilage degradation and joint inflammation. A previous study showed that microRNA (miR)­671­3p is involved in the development of OA, however, its function and molecular target in chondrocytes during the pathogenesis of OA remain to be fully elucidated. In the present study, miR­671­3p was significantly downregulated in knee OA cartilage tissues compared with normal cartilage tissues. The expression levels of pro­inflammatory cytokines, including interleukin (IL)­1ß, IL­6, IL­8 and tumor necrosis factor (TNF)­α, in the knee OA cartilage tissues were significantly higher than those in the normal cartilage tissues. Through gain­of­function and loss­of­function experiments, miR­671­3p was shown to significantly affect matrix synthesis gene expression, cell proliferation, apoptosis and inflammation in chondrocytes from patients with OA. Subsequent bioinformatics analysis identified potential target sites of the miR­671­3p located in the 3'untranslated region of TNF receptor­associated factor (TRAF3). The results of a dual­luciferase reporter assay showed that TRAF3 is a target gene of miR­671­3p. Western blot analysis demonstrated that miR­671­3p inhibited the gene expression of TRAF3. Furthermore, the restoration of TRAF3 markedly abrogated the effect of miR­671­3p. Taken together, the present study suggests that miR­671­3p may be important in the pathogenesis of OA through targeting TRAF3 and regulating chondrocyte apoptosis and inflammation, which may be a potential molecular target for OA treatment.

MiR-375 Mediates Chondrocyte Metabolism and Oxidative Stress in Osteoarthritis Mouse Models through the JAK2/STAT3 Signaling Pathway.

OBJECTIVE: The aim of this work was to determine the effect of miR-375 on chondrocyte metabolism and oxidative stress in osteoarthritis (OA) mouse models through the JAK2/STAT3 signaling pathway. METHODS: Chondrocytes were divided into control, IL-1ß, IL-1ß + miR-375 mimic, IL-1ß + miR-375 inhibitor, IL-1ß + miR-NC (negative control), and IL-1ß + miR-375 inhibitor + siJAK2 groups. The chondrocyte proliferation was determined by MTT assay, the superoxide dismutase (SOD) and malondialdehyde (MDA) levels by corresponding kits, and the chondrocyte apoptosis by TUNEL staining. Furthermore, OA mouse models were divided into Sham, OA + miR-NC, and OA + miRNA-375 antagomir groups. The pathological changes were observed, and the expressions of miR-375 and the JAK2/STAT3 pathway were determined by qRT-PCR and Western blotting, respectively. RESULTS: IL-1ß-induced chondrocytes had significant increases in miR-375 and MDA, with decreased proliferation and SOD levels, as compared to the control group. Meanwhile, they also exhibited elevated apoptosis, with upregulations of ADAMTS-5 and MMP-13 and downregulations of COL2A1 and ACAN, as well as decreased p-JAK2/JAK2, p-STAT3/STAT3, and Bcl-2/Bax. However, these changes were significantly improved after transfection with miR-375 inhibitor, but transfection with miR-375 mimic resulted in severer exacerbation. Notably, the improvement of miR-375 inhibitor could be abolished by transfection with siJAK2. Furthermore, miR-375 antagomir significantly alleviated OA progression in OA mice in vivo. CONCLUSION: MiR-375 suppression enhanced the ability of chondrocyte to antagonize the oxidative stress and maintained the homeostasis of extracellular matrix metabolism to protect chondrocytes from OA via activation of the JAK2/STAT3 pathway, indicating that miR-375 is a potential molecular target for OA treatment.

miR-29a inhibits adhesion, migration, and invasion of osteosarcoma cells by suppressing CDC42.

Osteosarcoma is one of the most common tumors of the bone in children and adolescents worldwide. The relapse and metastasis of osteosarcoma are a major therapeutic challenge. Recently, several metastasis regulators, including miRNAs, kinases, and lncRNAs, were reported in osteosarcoma. Identifying novel regulators of metastasis will be useful to explore novel biomarkers for osteosarcoma. The present study showed miR-29a overexpression significantly inhibited HOS and MG-63 cell adhesion, invasion, and migration. About 70% of the wound area was repaired by migrating cells after 24 h in the control group, and only 50% of the wound area was repaired in the miR-29a overexpression group. The numbers of invading cells were decreased by 40% and 50% in HOS and MG-63 cells transfected with miR-29a, respectively, compared with the negative control group. Moreover, the present study validated that CDC42 was a direct target of miR-29a in OS cells. In conclusion, miR-29a may serve as a therapeutic target for osteosarcoma.